<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103492</url>
  </required_header>
  <id_info>
    <org_study_id>11-07-46</org_study_id>
    <nct_id>NCT01103492</nct_id>
  </id_info>
  <brief_title>Treatment of Hemorrhagic Radiation Proctitis Using the Halo System</brief_title>
  <official_title>Treatment of Hemorrhagic Radiation Proctitis Using the Halo System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covidien, GI Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves evaluating a procedure in which the study device, the HALO90 Ablation
      catheter, is used to heat a thin layer of tissue lining the rectum using radiofrequency (RF)
      energy in subjects suffering from radiation proctitis (acute inflammation of the inner lining
      of the rectum caused by the side effects of radiation treatments that can lead to bleeding).

      In medical procedures, the RF energy used with this device, has been historically used in
      shrinking or removing soft-tissue, for surgical cutting, and for stopping bleeding. The
      device is cleared by the Food and Drug Administration (FDA) for use in coagulation (to assit
      with stoping bleeding and clotting of blood) of tissue within the digestive tract. The device
      has been used in areas outside the esophagus (inner lining of the throat), including the
      rectum to treat radiation proctitis. The stoppage of bleeding of radiation proctitis, using
      the HALO device, may be one method to control the bleeding.

      The purpose of this study is to evaluate the effectiveness and record the results of
      treatment of radiation proctitis using the HALO device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to prospectively gather information regarding the performance of an
      endoscope-mounted radiofrequency (RF) energy device, which utilizes RF energy for the
      coagulation of gastrointestinal tissue in the setting of bleeding of radiation proctitis. The
      study device, the HALO90 Ablation catheter, has an FDA 510(k) clearance for human use.

      The study design is a single-site, prospective clinical trial to gather performance data
      regarding a 510(k)-cleared, endoscopically-guided radiofrequency energy ablation device for
      the coagulation of hemorrhagic radiation proctitis.

      Study subjects will have experienced bloody stools due to proctitis following pelvic
      radiation for cancers of the prostate or uterine endometrium. The study will include female
      and male adult patients who have received pelvic radiotherapy for such indications as cancer
      of the prostate or endometrium and have subsequently experienced recurrent hemorrhagic
      radiation proctitis.

      As part of this protocol, focal areas of the epithelial lining of the diseased colon, rectum,
      and/or anus will be treated with the study device. The aim is to obtain information about the
      hemostatic effect of this device. The treatment settings evaluated in this study have been
      previously established with this device in the esophagus in &quot;treat and resect&quot; protocols, as
      well as in clinical trials for Barrett's esophagus with long-term follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>As this is a feasibility trial, the plan is to evaluate safety and efficacy in relation to adverse events in a small population (20 max) of patients.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pelvic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Ablation catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HALO90 Ablation catheter</intervention_name>
    <description>FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.</description>
    <arm_group_label>Ablation catheter</arm_group_label>
    <other_name>Coagulation</other_name>
    <other_name>Endoscopic Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of pelvic irradiation. (Last radiation treatment must be greater than 6 months
             prior.)

          2. Recurrent bloody stools.

          3. Symptoms for &gt; 3 months.

          4. No active infection or ulceration.

          5. Diagnosis of radiation proctitis by endoscopic criteria.

          6. Other sources of bloody stools, such as colon cancer, ulcerative colitis, or
             hemorrhoids, have been ruled out by prior colonoscopy.

          7. Age â‰¥ 18 years old.

          8. Subject is able to tolerate endoscopy and sedation.

          9. Subject agrees to participate, fully understands content of the informed consent, and
             signs the informed consent form (ICF).

        Exclusion Criteria:

          1. History of anal incontinence, rectal resection or anorectal malignancy.

          2. Presence of anorectal fistulae or stenoses preventing passage of the endoscope and
             device.

          3. Pregnancy and breastfeeding mothers

          4. Subject is unable to provide informed consent for this study.

          5. Pelvic irradiation within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey M. Marks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <results_first_submitted>March 29, 2011</results_first_submitted>
  <results_first_submitted_qc>March 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2011</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Jeffrey Marks, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>radiation proctitis</keyword>
  <keyword>pelvic radiotherapy</keyword>
  <keyword>rectal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proctitis</mesh_term>
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ablation Catheter</title>
          <description>Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ablation Catheter</title>
          <description>Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>As this is a feasibility trial, the plan is to evaluate safety and efficacy in relation to adverse events in a small population (20 max) of patients.</description>
        <time_frame>1 year</time_frame>
        <population>There was no analysis of the data. Feasibility study with only one subject enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Ablation Treatment</title>
            <description>Subjects with radiation proctitis who met inclusion criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>As this is a feasibility trial, the plan is to evaluate safety and efficacy in relation to adverse events in a small population (20 max) of patients.</description>
          <population>There was no analysis of the data. Feasibility study with only one subject enrolled</population>
          <units>partipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ablation Catheter</title>
          <description>Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Marks, MD</name_or_title>
      <organization>University Hospitals Case Medical Center</organization>
      <phone>216-983-4930</phone>
      <email>Jeffrey.Marks@uhhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

